Gland Pharma: Certificate Under SEBI (Depositories and Participants) Regulations, 2018 for Q3 FY25
Gland Pharma Limited submitted a confirmation certificate for the quarter ended December 31, 2025, under SEBI regulations. The certificate from its RTA, MUFG Intime India, confirms processing of dematerialised securities and adherence to listing and registration timelines.
This is a standard compliance filing related to share transfer and dematerialization processes, which is a routine operational activity and has no significant impact on the company's business or stock performance.
The announcement is a routine regulatory filing and does not contain any new financial information or strategic updates that would impact the company's sentiment.
Gland Pharma Limited has submitted a confirmation certificate for the quarter ended December 31, 2025, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was received from MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent.
The certificate confirms that securities received from depository participants for dematerialisation during the quarter were processed and confirmed with the depositories. It also states that the securities were listed on the respective stock exchanges, and the certificates were mutilated and cancelled after verification, with the depositories' names substituted in the register of members within the stipulated timelines.
MUFG Intime India Private Limited noted that no requests for dematerialization or rematerialization were received during the period. The announcement serves as an update for regulatory compliance and record-keeping purposes.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.